Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610 was the 14th innovative medicine that was approved of clinical trials. XZP is one small molecule agonist with high efficiency, high selectivity and novel structure that can significantly improve the steatosis, inflammation and fibrosis of the NASH animal model, with good pharmacokinetic properties and excellent safety. It is expected to be used in clinical practice and effectively treat NASH.
During the preclinical R&D, Medicilon was honored to participate in the pharmacokinetics tests and safety evaluation. Medicilon’s team delivered the part of results with profession and efficiency.